Pulmonary Fibrosis News Columnist and Forum Moderator Charlene Marshall reads an article examining the efficacy of Ofev among elderly patients living with IPF, who also had comorbidities. The 2021 study ultimately determined the benefits of Ofev were similar in elderly IPF patients and among those who had few or several comorbidities. However, patients who were older were more likely to discontinue use of Ofev due to adverse side effects such as diarrhea.

Are you interested in learning more about Pulmonary Fibrosis? If so, please visit: https://pulmonaryfibrosisnews.com